Eli Lilly and Company

LLY

US5324571083

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 06:47 pm

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

950.5 USD

Average target price

893.8 USD

Spread / Average Target

-5.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B
SANOFI	+2.41%	126B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 16/07/2024 BST			After market 21:27:42
941.6 ^USD	-0.93%		942.1	+0.05%

02:35pm	Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793	MT
09:00am	Novo owner backs Swiss biotech Asceneuron in $100 million round	RE

Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793	01:35pm	MT
Novo owner backs Swiss biotech Asceneuron in $100 million round	08:00am	RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	07-12	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	07-12	RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	07-12	MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating	07-12	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	07-12	RE
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	07-11	DJ
Pfizer moves forward with once-daily weight loss drug	07-11	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	07-11	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	07-11	MT
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating	07-11	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	07-10	RE
SANDERS SAYS HE IS CURRENTLY FOCUSED ON NOVO NORDISK BUT WILL 'C…	07-10	RE
Eli Lilly Names Gordon Brooks Interim Chief Financial Officer	07-10	DJ
Eli Lilly Appoints Gordon Brooks Interim CFO	07-10	MT
Barclays Adjusts Price Target on Eli Lilly to $1,025 From $913	07-10	MT
Eli Lilly Names Gordon Brooks Interim CFO	07-10	MT
DexCom, Inc. : A Must-Have Tool for Diabetes Care	07-10
Eli Lilly and Company Announces Chief Financial Officer Changes	07-10	CI
Eli Lilly and Company Announces Resignation of Anat Ashkenazi Resigned as Executive Vice President	07-10	CI
Analysis Shows Use of Novo Nordisk's Wegovy, Ozempic for Weight Loss Declines After Two Years	07-10	MT
Sellers of fake Ozempic to face charges in Austrian court	07-09	RE
Mixed feelings	07-09
VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	07-09	CI